Syncom Formulations schedules 38th AGM for September 30, 2026
- Syncom Formulations schedules 38th AGM for September 30, 2026
- Meeting will be held via video conferencing at 2:00 pm
- FY26 Annual Report filed with BSE and NSE on September 7, 2026
- Filing includes financial statements and regulatory reports

*this image is generated using AI for illustrative purposes only.
Syncom Formulations has scheduled its 38th Annual General Meeting (AGM) for September 30, 2026. The meeting will commence at 2:00 pm and be conducted through Video Conferencing or Other Audio Visual Means, in compliance with SEBI LODR regulations.
The company submitted the notice alongside its 38th Annual Report for the financial year ended March 31, 2026. The filing includes the balance sheet, profit and loss statement, cash flow statement, and statement of changes in equity.
Regulatory Compliance
The submission adheres to Regulation 34(1) of the SEBI (LODR) Regulations, 2015. The documents were filed on September 7, 2026, with both the Bombay Stock Exchange and the National Stock Exchange of India.
The annual report also contains the Board’s Report, Corporate Governance Report, Business Responsibility and Sustainability Report (BRSR), and the Auditors’ Report along with its annexures.
Accessing Documents
Shareholders and stakeholders can access the annual report and related documents on the company’s official website. The filings are also available on the respective exchange portals.
Vaishali Agrawal, Company Secretary and Compliance Officer, signed the submission digitally.
Historical Stock Returns for Syncom Formulations
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.51% | +4.16% | +52.41% | +67.11% | +18.19% | 0.0% |
How might the financial performance detailed in the 38th Annual Report influence Syncom Formulations' dividend policy or share buyback plans?
What specific sustainability initiatives outlined in the Business Responsibility and Sustainability Report (BRSR) could impact the company's long-term operational costs or regulatory standing?
Are there any proposed changes to the Board of Directors or executive compensation structures that shareholders should scrutinize during the upcoming AGM?


































